Leveraging the information from our in vivo pharmacokinetic analysis of STO-609, we demonstrate that pharmacological inhibition of CaMKK2 reverses the hallmarks of hepatic steatosis in two mouse models of NAFLD. This evidence concerns the gene CAMKK2 and fatty liver disease.